Automate Your Wheel Strategy on MBIO
With Tiblio's Option Bot, you can configure your own wheel strategy including MBIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MBIO
- Rev/Share 0.0
- Book/Share 0.6307
- PB 2.2991
- Debt/Equity 0.0
- CurrentRatio 1.3371
- ROIC -2.9973
- MktCap 6348300.0
- FreeCF/Share -1.3069
- PFCF -0.8489
- PE -0.7744
- Debt/Assets 0.0
- DivYield 0
- ROE 2.4844
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy
MBIO
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.
Read More
This BlackRock stock just spiked over 300%
MBIO
Published: July 07, 2025 by: Finbold
Sentiment: Positive
Published: July 07, 2025 by: Finbold
Sentiment: Positive
Shares of Mustang Bio (NASDAQ: MBIO) surged on Monday as investors responded to a significant approval from the Food and Drug Administration (FDA).
Read More
About Mustang Bio, Inc. (MBIO)
- IPO Date 2017-08-22
- Website https://www.mustangbio.com
- Industry Biotechnology
- CEO Manuel Litchman
- Employees 6
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.